Chinook Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview

Chinook Therapeutics

05/08/2023 03:03

* Chinook Therapeutics Inc  KDNY.OQ   KDNY.O  is expected
to show
a fall in quarterly revenue when it reports  results on August 7
(estimated). 
    * The Seattle Washington-based  company is expected to
report  a
42.6% decrease in revenue to $240 thousand from $418 thousand a
year ago, according to the mean estimate from 10 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Chinook
Therapeutics Inc
is for a loss of 81 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chinook
Therapeutics Inc is $40​, below​ its last closing price
of $40.28. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.79       -0.79      -0.85     Missed  -6.9
 Dec. 31 2023  -0.79       -0.79      -0.90     Missed  -13.9
 Sep. 30 2022  -0.63       -0.63      -0.83     Missed  -32.6​
 Jun. 30 2022  -0.61       -0.61      -0.61     Met     0.5
 ​​Mar.        -0.66       -0.67      -0.54     Beat    18.9
 31 2022                                                
 Dec. 31 2021  -0.75       -0.68      0.14      Beat    120.7​
 Sep. 30 2021  -0.88       -0.84      -0.69     Beat    17.7
 Jun. 30 2021  -0.79       -0.78      -1.14     Missed  -45.5
 This summary was machine generated August 5 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated